AMP IDIBELL

Accelerator
Meeting Point
{AMP III}

Third Edition (26th November 2020)

VIRTUAL

From bench to Market:
The Accelerator Meeting Point
drives the biomedical
innovation in Bellvitge

The AMP III is organised by IDIBELL’s Business Development & Innovation Area and aims to offer investors preferential access to innovation projects in different stages of development.

Previous editions

2019

AMP II (2nd edition)

Bellvitge Biomedical Research Institute (IDIBELL) celebrated the second edition of its Accelerator
Meeting Point (AMP), restating the success of the previous edition. This meeting is organised by IDIBELL’s business development and innovation area and aims to offer investors preferential access to innovation projects in their early stages.

RESEARCHERS 2019

Dr. Oriol Casanovas

Dr. Josep Maria Aran

Dr. Josep Maria Grinyó

Dra. Ethel Queralt

Dra. Maria Jose Linares

Dr. Angel Raya

Dr. Oscar Martinez-Tirado

Dra. Virginia Nunes

Dra. Eva Gonzalez

GUESTS 2019

Jordi Naval – BIOCAT
Michael Tadrós – Fundación Botín
Raül Delgado-Morales – IDIBELL
Marina Rigau Resina – IDIBELL
Esther Riambau – UPF
Laura Rodríguez Gallego – Healthequity
Ignasi Eras – Nina Capital
Melqui Calzado- CataloniaBio
Andrea Sáez – ASABYS
Sylvain Sachot – ASABYS
Lucas Martinez – DCN
Yuki Hasegawa – Whiz partners
Christoph Massner – Earlybird
Jöel Jean-Mairet – Ysios
Mireia Angulo Parera – Caixa C.R.
Sara Sanz – Inveready
Skyla Rabadi – Ship2B
Marc Ramis – Life BioScience
Francisco Armero – Cross Road Biotech
Pablo Cabello – Clave Mayor

2018

AMP I (1st edition)

The Bellvitge Biomedical Research Institute (IDIBELL) held yesterday April 16th the first edition of its
Accelerator Meeting Point, a meeting where CataloniaBio -association of biomedicine and health
companies in Catalonia-, Biocat -institution responsible for the promotion of the life sciences and
health sector in Catalonia- and Health Equity -Venture capital of the Barcelona Medical Associationspent
a day with researchers in order to provide recommendations for research projects at a stage
two to three years prior to reaching a commercial milestone.

RESEARCHERS 2018

Dr. Carles Soriano

Dra. Monica Povedano

Dra. Sara Larriba

Dra. Eva Gonzalez

Dr. Daniel Lorenzo

Dr. Josep Maria Aran

Dr. Francisco Ciruela

Dra. Mariona Graupera

Dr. Oriol Casanovas

Dr. Àngel Raya

Dra. Àngels Fabra

GUESTS 2018

CataloniaBio

Biocat

Health Equity

Chasing Science

Universal Doctor

Projects

+ 0

Attendees

B2B Meetings

Agenda

This third edition has been reorganized into a VIRTUAL format. The conference will have two rooms, dividing the projects according to their state of development, establishing 10 projects per room with a total of 20 in the event.

The guests have also been divided into two rooms (according to the projects preselected in the registration), the first one mainly dominated by investors and the second one highlighted by the presence of biotechnology and health sector companies.

At the end of the projects presentations in front of the investors and companies, there is the possibility of selecting the projects that have aroused their interest, and B2B meeting will be scheduled to their availability in the following days.

09:00

Opening and Welcome:

Gabriel Capellá, IDIBELL Director

Raquel Egea, Innovation & Business Development Area Director

09:00

09:20

Project Pitching Sesion 1

Virtual Room 1 (Investment):
- 9:20h Remab (Dr. Rafael Máñez)
- 9:40h Tractivus (Dr. Joan Gilabert)
- 10:00h Angiotheragnostics (Dra. Gabriela Jimenez)
- 10:20h PURPOSE (Dr. Josep M. Aran)
- 10:40h APTADEL (Dr. Óscar Martínez-Tirado)

Virtual Room 2 (I+D / Collaboration):
- 9:20h NeurAntigen: diagnostic kit with hiPSC for autoimmune encephalopathy (Dra. Mertixell Pons)
- 9:40h Exosomal miRNAs in seminal plasma as non-invasive markers of prostate cancer diagnosis (Dra. Sara Larriba)
- 10:00h An Endo-Luminar Linear Anastomosis (ELLA) Stapler (Dr. Thomas Golda)
- 10:20h Pharmacological modification of the tumour stroma in hepatic metastases from colorectal carcinoma (Dr. David García Molleví)
- 10:40h Cohesin synthetic lethal mutations as a new cancer therapeutic approach (Dra. Ethelvina Queralt)

09:20

11:00

Project Pitching Sesion 2

Virtual Room 1 (Investment)
- 11:00h NELA: Disruptive Endolmedular Implants for Hip Replacements (Dr. José Expósito)
- 11:20h PACIENA: An optimized neo-vaginal prothesis (Clara Gómez)
- 11:40h Doppli Connect (José Alberola, Roberto García)
- 12:00h VCN Bioscience (Dr. Manel Cascallo)

Virtual Room 2 (I+D / Collaboration):
- 11:00h HistShock: Diagnostic and pronostic kit for sepsis and septic shock (Dr. Jose Luís García)
-11:20h Tackling radiation-induced enteritis (Dr. Jordi Guiu)
- 11:40h Drivers, oncogenes and funambulists in low-grade brain tumors (Dra. Barbara Polo)
- 12:00h Biomarkers of prostate cancer agressiveness (Dr. Xavier Ruiz)
- 12:20 BioPAPER: A Rapid Test for Personalizing Antibiotic Treatments Against Respiratory Infections in Hospitals (Dr. Roberto de la Rica)

11:00

13:00

Closing & B2B meetings

(Will be scheduled in the following days according to your interest and availability in the following days)

13:00

Projects

ROOM 1

RemAb: Preventing MDR Gram-negative hospital-acquired infections

(Dr. Rafael Mañez, Dr. Daniel Bello / IDIBELL)

VCN Biosciences: next-generation oncolytic adenoviruses turning cold tumors into hot

(Dr. Manel Cascalló / IDIBELL)

Tractivus: Avoid Bacteria Infections

(Dr. Joan Gilavert / IDIBELL)

PURPOSE: C4BP-based biologics as novel immunomodulators.

(Dr. Josep Maria Aran / IDIBELL)

APTADEL: Multifunctional RNA molecules to treat Ewing Sarcoma

(Dr. Oscar Martínez / IDIBELL)

Angiotheragnostics: First-in-Class anticancer treatment with its patient selection biomarker to overcome therapy resistance

(Dr. Oriol Casanovas / IDIBELL)

NELA: Disruptive Endomedular Implants for Hip Replacements

(Dr. José Exposito Ollero / INCLIVA)

PACIENA: An optimized neo-vaginal prothesis

(Clara Gómez / FISABIO)

Doppli Connect

(Dr. Jose Alberola, Roberto García / IIS la Fe)

ROOM 2

NeurAntigen, diagnostic kit with hiPSC for autoimmune encephalopathy

(Dra. Antonella Consiglio / IDIBELL)

Deep Cognitive Estimulation System by Sound Interface (DCESSI).

(Dr. Pere Cardona / IDIBELL)

An Endo-Luminar Linear Anastomosis (ELLA) Stapler

(Dr. Thomas Golda / IDIBELL)

Pharmacological modification of the tumour stroma in hepatic metastases from colorectal carcinoma

(Dr. David García Molleví / IDIBELL)

Cohesin synthetic lethal mutations as a new cancer therapeutic approach

(Dra. Ethelvina Queralt / IDIBELL)

Exosomal miRNAs in seminal plasma as non-invasive markers of prostate cancer diagnosis

(Dra. Sara Larriba / IDIBELL)

Tackling radiation-induced enteritis

(Dr. Jordi Guiu / IDIBELL)

Biomarkers of prostate cancer agressiveness

(Dr. Xavier Ruiz / IISPV)

Histshock: Diagnostic and prognostic kit for sepsis and septic shock

(Dr. Jose Luís García / INCLIVA)

Drivers, oncogenes and funambulists in low-grade brain tumors

(Dra. Bárbara Polo / IDIBELL)

BioPAPER: A Rapid Test for Personalizing Antibiotic Treatments Against Respiratory Infections in Hospitals

(Dr. Roberto de la Rica / IdISBa and UIB)

With the aim of strengthening the future Mediterranean alliance AIISEM (Alianza de Innovación e Industralización Sanitaria del Eje Mediterráneo), the third edition of the AMP will also count with the participation projects from the following research centers/institutions: ISABIO, INCLIVA, IIS la Fe, IdISBa, IMIB and IISPV.